Sequana Medical Achieves First U.S. Commercial Implantation of alfapump® System at Mount Sinai Hospital
Key Insights
Sequana Medical (search) successfully completed the first commercial implantation of its alfapump® System in the United States at Mount Sinai Hospital in New York, marking a key milestone following FDA approval in December 2024.
The alfapump System (search) is the first active implantable medical device approved in the U.S. for treating recurrent or refractory ascites (search) due to liver cirrhosis (search), automatically removing fluid from the abdomen to the bladder.
The company estimates approximately 70,000 U.S. patients currently suffer from this condition, representing a market opportunity exceeding $2 billion, projected to reach 130,000 patients and over $5 billion by 2035.
Sequana Medical (search) NV has achieved a significant commercial milestone with the successful completion of the first U.S. implantation of its alfapump® System at Mount Sinai Hospital in New York. This breakthrough represents the culmination of years of clinical development and marks the beginning of commercial availability for a revolutionary treatment addressing recurrent or refractory ascites (search) due to liver cirrhosis (search).
The alfapump System (search) stands as the first active implantable medical device approved by the FDA for this indication, offering an automated solution that continuously removes ascites fluid from the abdomen into the bladder for elimination through normal urination. The device received FDA Premarket Approval (PMA) in December 2024, following Breakthrough Device Designation granted in 2019.
Clinical Impact and Market Opportunity
Recurrent or refractory ascites (search) affects approximately 70,000 patients in the United States, creating a substantial unmet medical need. Current standard treatment involves therapeutic paracentesis, an invasive procedure requiring large needle insertion to drain abdominal fluid. Patients typically undergo this burdensome procedure weekly or monthly, necessitating frequent hospital visits and significantly disrupting daily life.
Dr. Rahul Patel, Assistant Professor of Radiology and Surgery at Icahn School of Medicine at Mount Sinai, emphasized the transformative potential of this technology: "The alfapump represents a significant advancement for our patients suffering from recurrent ascites. For too long, these patients have had to put up with repeated needle punctures, burdensome procedures to drain the ascites fluid. With the alfapump system (search), patients have this done automatically and continuously, avoiding the punctures and the hospital visits, and maintaining a flat abdomen."
Sequana Medical (search) projects the market opportunity to exceed $2 billion currently, with forecasts indicating growth to 130,000 patients and over $5 billion by 2035. This expansion is primarily driven by increasing rates of NASH/MASH (search) and alcoholic liver disease (search), conditions closely linked to rising obesity rates.
Clinical Evidence and Efficacy
The alfapump System (search)'s approval was supported by data from the POSEIDON study, a landmark clinical trial conducted across 18 centers in the United States and Canada. The pivotal cohort of 40 patients demonstrated remarkable outcomes at both 6 and 24 months post-implantation, showing virtual elimination of therapeutic paracentesis requirements and significant improvement in quality of life measures.
Quality of life improvements were assessed using the SF-36 Physical Component Summary (PCS) for subjective physical health and the Ascites Q questionnaire for ascites-specific symptoms. These validated instruments provided objective evidence of the device's clinical benefit beyond the primary endpoint of reducing paracentesis procedures.
Commercial Strategy and Market Access
Sequana Medical (search) is executing a focused commercialization approach through a specialty sales force targeting the 90 U.S. liver transplant centers that perform more than 90% of liver transplants annually. This strategic focus leverages the expertise and patient population concentration at these specialized centers.
The commercial rollout received additional support from the Centers for Medicare & Medicaid Services (CMS), which approved New Technology Add-on Payment for the alfapump when performed in hospital inpatient settings, effective October 1, 2025. This reimbursement decision facilitates broader patient access to the technology.
Ian Crosbie, Chief Executive Officer of Sequana Medical (search), expressed confidence in the market opportunity: "Having recently returned from the annual meeting of the AASLD (American Association for the Study of Liver Diseases) in Washington DC, I am more excited than ever about the US market opportunity for the alfapump. At the meeting, I met with many US hepatologists and time after time I heard they share our vision of the alfapump replacing repeated puncture paracentesis in many of their patients."
Safety Profile and Clinical Considerations
The alfapump System (search) carries specific safety considerations that healthcare providers must carefully evaluate. The device is MRI unsafe due to potential pump movement, circuitry damage, and catheter dislocation risks. Hyperbaric oxygen therapy is also contraindicated due to environmental conditions exceeding the device's operational parameters.
Potential adverse events include pump pocket hematoma, skin erosion, infection, pump migration, and catheter complications. The implantation procedure may result in infections that could impact liver transplant timing or listing status. Additional risks encompass peritoneal cavity infections, coagulopathy, bladder capacity limitations, and obstructive uropathy.
Healthcare providers must also consider potential interactions with various medical procedures and therapies, including supersonic therapy, TENS units, lithotripsy, defibrillation, radiation therapy, and electrocautery procedures.
Pipeline Development
Beyond the alfapump System (search), Sequana Medical (search) continues advancing its DSR® (Direct Sodium Removal) therapy platform for heart failure (search) applications. Results from the RED DESERT and SAHARA proof-of-concept studies, published in the European Journal of Heart Failure in April 2024, support DSR's mechanism in breaking the cardiorenal syndrome (search) cycle.
The ongoing MOJAVE study, a U.S. randomized controlled multi-center Phase 1/2a clinical trial, has shown promising early results. All three patients in the non-randomized cohort experienced dramatic improvements in diuretic response, with a mean 326% increase in six-hour urinary sodium excretion at three months and a 95% reduction in loop diuretic requirements. The independent Data Safety Monitoring Board has approved progression to the randomized cohort of up to 30 additional patients, pending additional financing.